Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

BACKGROUND AND AIMS: Tofacitinib is an oral small molecule Janus kinase [JAK] inhibitor for the treatment of ulcerative colitis. We report an integrated summary of tofacitinib safety [exposure: ≤7.8 years] from the global clinical programme. METHODS: Patients receiving tofacitinib 5 or 10 mg twice d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, D’Haens, Geert R, Sands, Bruce E, Panaccione, Remo, Ng, Siew C, Lawendy, Nervin, Kulisek, Nicole, Modesto, Irene, Guo, Xiang, Mundayat, Rajiv, Su, Chinyu, Vranic, Ivana, Panés, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069618/
https://www.ncbi.nlm.nih.gov/pubmed/36124702
http://dx.doi.org/10.1093/ecco-jcc/jjac141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069618/
https://www.ncbi.nlm.nih.gov/pubmed/36124702
http://dx.doi.org/10.1093/ecco-jcc/jjac141

Ejemplares similares